Search
Search
Search results 45
AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award
The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).
News & Events
AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market
Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx
News & Events
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market
Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market
Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The
News & Events
AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market
Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology compa
News & Events
AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement
Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies i
News & Events
AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection
Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.
News & Events
AmoyDx ROS1 Kit Approval in Taiwan, China
Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan, China Food and Drug Administration(TFDA).
News & Events
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
News & Events
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
Pan Lung Cancer PCR Panel
PRODUCTS
Multi-Gene Mutations Detection Kit
PRODUCTS
MET Mutation Detection Kit
PRODUCTS
Super-ARMS® EGFR Mutation Detection Kit
The best solution for Plasma EGFR Mutation Testing
PRODUCTS
EGFR 29 Mutations Detection Kit
PRODUCTS
EML4-ALK Fusion Gene Detection Kit
PRODUCTS
ROS1 Gene Fusions Detection Kit
PRODUCTS
BRAF V600 Mutations Detection Kit
PRODUCTS
KRAS/NRAS Mutations Detection Kit
PRODUCTS
KRAS/NRAS/BRAF Mutations Detection Kit
PRODUCTS
C-KIT Mutation Detection Kit
PRODUCTS
HANDLE Classic NGS Panel
PRODUCTS
Essential NGS Panel
A precise NGS panel, focus on 10 essential genes for clinical target therapy.
PRODUCTS
HER-2 Gene Amplification Analysis Kit
PRODUCTS
Human Papillomavirus (HPV) Genotyping Detection Kit
PRODUCTS
DNA and RNA Extraction Kits
PRODUCTS
Multi-Gene-L1-01 Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non–small cell lung cancer
DOWNLOAD
Multi-Gene-L1-01 Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non–small cell lung cancer
DOWNLOAD
LCP32-L2-01 ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research
DOWNLOAD
HPV21-L2-03 SMARCB1INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity
DOWNLOAD
Extraction-L1-02 Malignant glomus tumor of the ileum mimicking GIST with distant metastasis without BRAF V600E mutation
DOWNLOAD
MSDS-MET-202001
DOWNLOAD
BRAF-L2-02 BRAFV600E and NRASQ61L_Q61R mutation analysis in metastatic melanoma using immunohistochemistry_ a study of 754 cases
DOWNLOAD
AmoyDx® MET Mutation Detection Kit-B1.2-24T
DOWNLOAD
ROS1-L1-03 Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
DOWNLOAD
EML4-ALK-L1-04 High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients
DOWNLOAD
EGFR-L1-02 Sensitive Detection of EGFR Mutations in Cerebrospinal Fluid from Lung Adenocarcinoma Patients with Brain Metastases
DOWNLOAD
no more...
AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award
The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).
News & Events
AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market
Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx
News & Events
AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market
Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.
News & Events
AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market
Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The
News & Events
AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market
Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology compa
News & Events
AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement
Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies i
News & Events
AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection
Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.
News & Events
AmoyDx ROS1 Kit Approval in Taiwan, China
Recently AmoyDx ROS1 gene fusion detection kit (fluorescence PCR method) was approved by Taiwan, China Food and Drug Administration(TFDA).
News & Events
AmoyDx® Essential NGS panel approval from Chinese authority
AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell
News & Events
AmoyDx ROS1 Gene Fusions Detection Kit was Approved by South Korea MFDS as Companion Diagnostics for Pfizer's Crizotinib
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
News & Events
AmoyDx attended News Conference of Xalkori ROS1 approval in Japan
On June 23, Pfizer Oncology and Merck KGaA held a News Conference in Tokyo launching Xalkori (Crizotinib) ROS1 approval for additional indication. Xalkori, as a lung cancer targeted drug developed by Pfizer.
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.
News & Events
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple
News & Events
AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported
News & Events
no more...
Inquiry
* Required information
Manage your account info
Change your password